Therapeutic Respiratory Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Therapeutic Respiratory Devices Market Report is Segmented by Product (Positive Airway Pressure Devices, Humidifiers, Nebulizers, Oxygen Concentrators, Ventilators, Inhalers, and More), Application (COPD, Asthma, Obstructive Sleep Apnea, and More), End User (Hospitals, Homecare Settings, and More) and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD) and Volume (Units).

Therapeutic Respiratory Devices Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Therapeutic Respiratory Devices Market with other markets in Healthcare Industry

Therapeutic Respiratory Devices Market Analysis by Mordor Intelligence

The Therapeutic Respiratory Devices Market size is estimated at USD 15.35 billion in 2025, and is expected to reach USD 22.19 billion by 2030, at a CAGR of 7.65% during the forecast period (2025-2030). Widening adoption of home-care treatment models, rapid diffusion of digital therapeutics, and steady innovation in miniaturised oxygen systems underpin this growth trajectory. Demand also benefits from rising chronic obstructive pulmonary disease (COPD) prevalence, an ageing population that increasingly requires long-term oxygen therapy, and payer willingness to reimburse connected devices that demonstrably cut readmission costs. Competitive pressure is intensifying as manufacturers fold artificial-intelligence (AI) analytics into positive airway pressure (PAP) platforms, while supply-chain resilience has become a core differentiator after semiconductor shortages disrupted component flows. Regionally, North America continues to generate the bulk of revenue, yet Asia-Pacific is outpacing all other regions on the back of hospital infrastructure expansion and broader access to diagnostics.    

Key Report Takeaways

  • By product type, positive airway pressure devices held 35.45% of the therapeutic respiratory devices market share in 2024, whereas connected inhalers are projected to post an 8.75% CAGR to 2030.  
  • By application, COPD accounted for 43.12% of the therapeutic respiratory devices market size in 2024; sleep apnea is forecast to expand at 8.63% CAGR through 2030.  
  • By end user, hospitals controlled 51.34% revenue share in 2024, while the home-care segment is growing fastest at 9.22% CAGR.  
  • By geography, North America led with 39.76% revenue contribution in 2024, but Asia-Pacific is projected to record an 8.99% CAGR to 2030.  

Segment Analysis

By Product: PAP Devices Lead Innovation Wave

Positive airway pressure systems commanded 35.45% revenue in 2024, maintaining first position within the therapeutic respiratory devices market. ResMed’s fabric-lined AirTouch N30i mask won 92.6% preference among experienced users, underscoring how comfort upgrades can lift compliance. Inhalers, supported by AI-driven monitoring, represent the fastest-growing product category at 8.75% CAGR, signalling an imminent pivot toward drug-device hybrids that capture usage data.  

Humidifiers and nebulisers are benefiting from paediatric high-flow therapies that shave 0.65 days off inpatient stays. Concentrators are evolving through Nitroxy molecular sieves that elevate purity and battery life. Ventilator portfolios are consolidating after Medtronic exited the acute-care segment to focus on integrated monitoring. Airway-clearance devices such as Simeox 200 show how oscillatory vibration can expand treatment options for bronchiectasis.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Application: Sleep Apnea Accelerates Past COPD Growth

COPD remains the largest application with 43.12% market share in 2024, reflecting the sizeable disease burden. However, sleep apnea is growing faster at 8.63% CAGR as diagnostic tools proliferate and therapies broaden. The Inspire V hypoglossal-nerve stimulator illustrates how neurostimulation is carving a niche for moderate-to-severe obstructive cases.  

Asthma management is improving through smartwatch-based predictive analytics that warn of attacks using environmental and physiological cues. Other indications, such as cluster headaches treated with home oxygen, signal diversification beyond core pulmonary diseases. Gene-delivery systems that transport mRNA therapies directly to lung tissue herald long-term growth avenues.

By End User: Home-Care Settings Reshape Delivery Models

Hospitals held 51.34% of 2024 revenue within the therapeutic respiratory devices market. Yet home-care environments are expanding at 9.22% CAGR, supported by connected devices that transmit usage and physiological data directly to clinicians. Portable concentrator rentals generate stable cash flows under multiyear Medicare contracts.  

Ambulatory clinics are scaling diagnostic capacity with compact sleep-testing rigs, while long-term care facilities equip resident rooms with low-noise concentrators to meet geriatrics needs. Monthly home oxygen costs averaging USD 65 underscore the economic appeal relative to institutional care. Devices such as FlexO2 empower patients to titrate flow, reducing caregiver workload.

Market Share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America generated 39.76% of global revenue in 2024 by leveraging robust reimbursement and early uptake of digital therapeutics, yet growth in the region is moderating as penetration rates rise. The therapeutic respiratory devices market size for North America is forecast to increase steadily but below the Asia-Pacific pace. Recent CDC infection-control directives are shaping product specifications focused on aerosol-reduction and single-patient use.  

Asia-Pacific is the fastest-growing territory, projected at 8.99% CAGR through 2030. Governments are investing in hospital infrastructure and local manufacturing, while India positions its device sector for global prominence by 2025. Regional demand is further buoyed by urban air-quality deterioration and the rising prevalence of sleep-disordered breathing. Local firms are forming joint ventures with multinationals to bring cost-optimised PAP systems to market, supported by e-commerce channels that bypass traditional distribution bottlenecks.  

Europe maintains mid-single-digit expansion, sustained by harmonised regulatory frameworks and clinical excellence in tertiary centres. In the Middle East and Africa, market entry remains challenged by procurement cycles and funding variability, yet notable progress is evident. Saudi Arabia registered 5,462 respiratory therapy practitioners by January 2024, reinforcing clinical capacity for device deployment.

CAGR (%)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Competitive Landscape

The therapeutic respiratory devices market exhibits moderate concentration. ResMed posted USD 1.3 billion in quarterly revenue, reflecting 8% year-over-year growth, driven by cloud-connected PAP ecosystems. Philips, meanwhile, is rebuilding its U.S. franchise under a consent decree following large-scale product recalls.  

Fisher & Paykel Healthcare secured patents for nasal-seal interfaces that enhance fit across diverse facial geometries. The competitive landscape increasingly rewards companies that can demonstrate measurable clinical outcomes through real-world evidence, with digital biomarkers and remote monitoring capabilities becoming essential differentiators in both clinical adoption and reimbursement negotiations.

Strategic focus is shifting from standalone hardware to outcomes-based platforms that combine device, software, and coaching services. Industry players allocate roughly 7% of revenue to R&D, prioritising AI algorithms that flag non-adherence or predict exacerbations. Strengthening supply-chain redundancy and embedding antimicrobial surfaces in new models address post-pandemic procurement criteria

Therapeutic Respiratory Devices Industry Leaders

  1. ResMed Inc.

  2. Koninklijke Philips N.V.

  3. Fisher & Paykel Healthcare Ltd

  4. Drägerwerk AG & Co. KGaA

  5. GE HealthCare

  6. *Disclaimer: Major Players sorted in no particular order
Therapeutic Respiratory Devices Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • October 2024: Honeywell has entered into a long-term supply agreement with DevPro Biopharma. Together, they aim to develop a respiratory inhaler that prioritizes patient well-being and minimizes carbon emissions typically linked to conventional inhalers.
  • March 2024: Vapotherm announced plans to debut new home ventilator aimed at enhancing patient care, addressing growing demand for effective home care solutions in respiratory therapy
  • April 2023: OxyGo announced the launch of OxyHome 5L Stationary Concentrator, specifically designed to provide continuous oxygen flow of up to 5 liters per minute for use at home.

Table of Contents for Therapeutic Respiratory Devices Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing prevalence of COPD & asthma
    • 4.2.2 Surging adoption of home-care respiratory support
    • 4.2.3 Technological advances in PAP & portable O₂ concentrators
    • 4.2.4 Reimbursement expansion for long-term oxygen therapy
    • 4.2.5 Miniaturised high-flow nasal cannula systems for pediatrics
    • 4.2.6 AI-enabled connected inhalers boosting adherence
  • 4.3 Market Restraints
    • 4.3.1 Device capital cost & limited payor coverage in EMs
    • 4.3.2 Supply-chain fragility for critical components
    • 4.3.3 Infection-control concerns with aerosol-generating devices
    • 4.3.4 Rare-earth dependency for high-grade O₂ sieve beds
  • 4.4 Regulatory Landscape
  • 4.5 Technological Outlook
  • 4.6 Porter’s Five Forces Analysis
    • 4.6.1 Threat of New Entrants
    • 4.6.2 Bargaining Power of Buyers
    • 4.6.3 Bargaining Power of Suppliers
    • 4.6.4 Threat of Substitutes
    • 4.6.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value)

  • 5.1 By Product
    • 5.1.1 Positive Airway Pressure Devices
    • 5.1.2 Humidifiers
    • 5.1.3 Nebulizers
    • 5.1.4 Oxygen Concentrators
    • 5.1.5 Ventilators
    • 5.1.6 Inhalers
    • 5.1.7 Other Therapeutic Devices
  • 5.2 By Application
    • 5.2.1 COPD
    • 5.2.2 Asthma
    • 5.2.3 Obstructive Sleep Apnea
    • 5.2.4 Other Applications
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Home-care Settings
    • 5.3.3 Ambulatory Surgical and Specialty Clinics
    • 5.3.4 Long-term Care Facilities
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Koninklijke Philips N.V.
    • 6.3.2 ResMed Inc.
    • 6.3.3 Fisher & Paykel Healthcare Ltd
    • 6.3.4 Drägerwerk AG & Co. KGaA
    • 6.3.5 GE Healthcare
    • 6.3.6 Medtronic plc
    • 6.3.7 Smiths Group plc (Smiths Medical)
    • 6.3.8 Vyaire Medical Inc.
    • 6.3.9 Teleflex Incorporated
    • 6.3.10 Hamilton Medical AG
    • 6.3.11 Nihon Kohden Corp.
    • 6.3.12 Löwenstein Medical SE
    • 6.3.13 OMRON Healthcare
    • 6.3.14 Drive DeVilbiss Healthcare
    • 6.3.15 Invacare Corporation
    • 6.3.16 Nidek Medical Products Inc.
    • 6.3.17 ZOLL Medical Corporation
    • 6.3.18 Microlife Corp.
    • 6.3.19 Apex Medical Corp.

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Therapeutic Respiratory Devices Market Report Scope

As per the report's scope, therapeutic respiratory devices are medical tools used to manage and treat respiratory conditions by assisting breathing. The devices help deliver medication directly to the lungs or maintain open airways, improving the quality of life for patients with respiratory issues.

The therapeutic respiratory devices market is segmented by product, applications, and end-users. In terms of product, the market is segmented as positive airway pressure devices, ventilators, humidifiers, oxygen concentrators, nebulizers, inhalers, and others. By application, the market is segmented into asthma, COPD, obstructive sleep apnea, and others. By end-user, the market is segmented into hospitals, home care settings, and others. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD) for the above segments.

By Product Positive Airway Pressure Devices
Humidifiers
Nebulizers
Oxygen Concentrators
Ventilators
Inhalers
Other Therapeutic Devices
By Application COPD
Asthma
Obstructive Sleep Apnea
Other Applications
By End User Hospitals
Home-care Settings
Ambulatory Surgical and Specialty Clinics
Long-term Care Facilities
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Middle East and Africa GCC
South Africa
Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Product
Positive Airway Pressure Devices
Humidifiers
Nebulizers
Oxygen Concentrators
Ventilators
Inhalers
Other Therapeutic Devices
By Application
COPD
Asthma
Obstructive Sleep Apnea
Other Applications
By End User
Hospitals
Home-care Settings
Ambulatory Surgical and Specialty Clinics
Long-term Care Facilities
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Middle East and Africa GCC
South Africa
Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the therapeutic respiratory devices market?

The market is valued at USD 15.35 billion in 2025 and is projected to reach USD 22.19 billion by 2030.

Which region is expanding fastest in the therapeutic respiratory devices market?

Asia-Pacific is forecast to grow at an 8.99% CAGR through 2030, outpacing all other regions.

Which product category leads revenue share today?

Positive airway pressure systems hold 35.45% revenue, maintaining the top spot.

Why are connected inhalers gaining traction?

AI-enabled sensors improve adherence and clinical outcomes, driving an 8.75% CAGR for inhalers.

How quickly is the home-care segment growing?

Home-care settings are advancing at 9.22% CAGR thanks to reimbursement expansion and remote-monitoring capabilities.

What supply-chain risks affect manufacturers?

Semiconductor shortages and rare-earth dependency for zeolite sieve beds remain key vulnerabilities, prompting near-shoring and diversification strategies.

Page last updated on: June 22, 2025